Moderna is possibly the first biotech unicorn, and in 2018 was valued at 7.5 billion US dollars. According to this fortune magazine article in 2015, the company’s core technology is designed to help people make medicines within their own cells, rather than create something in a lab which patients need to ingest or inject which is how other biotech companies operate. The idea is for the patients to heal themselves. The writer claims that this would make Moderna’s products significantly faster to test and cheaper to buy.
If all requirements are met, the Vaccine could be made available by this time next year.
Another U.S based biotech company claims that they have actually identified a vaccine and is now in the process of manufacturing it. Guess what, they also claim their method is much faster!
Their approach is self-replicating RNA, where they would inject a very minute amount into your arm and it would create the antigen for a few weeks and would continue to do so itself. The amount of vaccine they’re aiming to use is a dose in micrograms so their vaccine is available to the largest population. The CEO, Joseph Payne says, this is something that sets them apart from their competition.
Sometime next year, if we’re lucky
Israel based biopharmaceutical company Kamada is developing a blood-plasma derived treatment against the coronavirus.
“The concept that we are developing is not new. People that are exposed to a virus develop antibodies for that virus….If patients who have recovered from the disease and are in convalescence donate plasma, there is a very good likelihood that in that plasma there are going to be antibodies.” The CEO of Kamada told the Jerusalem based publication.
Since the treatment Kamada is working on is supposed to serve severely ill patients, the process to develop it does not require a complete clinical trial as is the case with a new drug – and therefore, it might be expedited. That being said, we don’t have an official timeline by Kamada as yet.
The Chinese government has given the go-ahead for researchers to begin human safety tests of an experimental coronavirus vaccine. The vaccine has been created by Researchers at China’s Academy of Military Medical Sciences who are also closely affiliated with the People’s Liberation Army (PLA)
Chinese clinical trial registration database shows that the Phase one will test 108 healthy people between March 16 and Dec. 31. It too, will most likely arrive next year.
There are currently more than 35 companies and academic institutions which are racing to create a vaccine or a cure. According to experts at WHO, at best the earliest vaccine would be available by next year. Moderna, having had the first human trials, seems to be leading the pack at the moment.